Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ayodeji Adegunsoye, Justin M. Oldham, Evans R. Fernández Pérez, Mark Hamblin, Nina Patel, Mitchell Tener, Deepa Bhanot, Lacey Robinson, Sam Bullick, Lena Chen, Scully Hsu, Matthew Churpek, Donald Hedeker, Steven Montner, Jonathan H. Chung, Aliya N. Husain, Imre Noth, Mary E. Strek, Rekha Vij. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017

Member's Comments

No comment yet.

Related content which might interest you: Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Hypersensitivity pneumonitis associated with the use of temozolomide Source: Eur Respir J 2009; 33: 931-934 Year: 2009 Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis Source: Virtual Congress 2020 – Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis Year: 2020 Criteria for PF-ILD in a cohort of patients with chronic hypersensitivity pneumonitis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Factors predicting response to azathioprine in chronic hypersensitivity pneumonitis – the importance of BAL lymphocytosis Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment Year: 2018 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis Source: Eur Respir J, 57 (3) 2002872; 10.1183/13993003.02872-2020 Year: 2021 Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020 Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease Source: International Congress 2017 – Novel and old entities Year: 2017 Mechanisms of exercise limitation in patients with chronic hypersensitivity pneumonitis Source: ERJ Open Res, 4 (3) 00043-2018; 10.1183/23120541.00043-2018 Year: 2018 Diagnosis, course and management of hypersensitivity pneumonitis Source: Eur Respir Rev, 31 (163) 210169; 10.1183/16000617.0169-2021 Year: 2022 Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases I Year: 2016 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Prevalance and outcomes of pulmonary hypertension in chronic hypersensitivity pneumonitis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Interstitial pneumonia vs. hypersensitivity pneumonitis with autoimmune features Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Impact of mycophenolate mofetil on lung function in chronic hypersensitivity pneumonitis and connective tissue disease related-ILD Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015